Clinical trial
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00004049 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00004049 |
|---|---|
| Title | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| Official title | A Phase I and Pharmacokinetic Study of SR-45023A Administered Once Every 7 Days |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | apomine |
| Enrollment | 36 |
| Start date | Apr 1, 1999 |
| First posted | May 3, 2004 |
| Last update posted | Aug 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: